Vitiligo: Skin Malignancies and Tumor Suppressive Marker P53
نویسندگان
چکیده
منابع مشابه
p53 in hematologic malignancies.
T HE p53 HAS BEEN CHOSEN as molecule of the year for 1993 by the journal Science.' The protein's illustrious history began quietly in 1979, when a 53-kD eukaryotic protein was shown to bind to SV40 large T The protein was named p53 because of its size. Initial studies suggested that p53 was an oncogene because it could transform rodent ~ e l l s . ~ ' ~ The p53 genes used in these studies h...
متن کاملinhibin as a tumor marker in postmenopausal women with ovarian malignancies
background: inhibin is a dimeric glycoprotein that has a depressive effect on the anterior hypophyse secretion. the level of this tumor marker is undetectable in menopause women. in patients with gynecological cancer, especially granulosa and epidermal-type (mucinous), ovarian cancers considerable increase in the serum level of inhibin has been reported. the increased level of inhibin has been ...
متن کاملAberrations of the tumor suppressor p53 gene and p53 protein in solar keratosis in human skin.
Aberrations of the p53 gene in 27 solar keratoses were examined by the polymerase chain reaction and single-strand conformation polymorphism and DNA sequencing analyses. In a series of Japanese patients, eight of 27 cases (30%) of solar keratosis showed structural abnormalities of the p53 gene. Six of eight aberrations of p53 gene were determined to be single nucleotide substitutions, and five ...
متن کاملGrowth-Inhibitory and Tumor- Suppressive Functions of p53 Depend on Its Repression of CD44 Expression
The p53 tumor suppressor is a key mediator of cellular responses to various stresses. Here, we show that under conditions of basal physiologic and cell-culture stress, p53 inhibits expression of the CD44 cell-surface molecule via binding to a noncanonical p53-binding sequence in the CD44 promoter. This interaction enables an untransformed cell to respond to stress-induced, p53-dependent cytosta...
متن کاملTreatment of skin malignancies.
Malignant melanomas in situ can usually be treated in consultation with a specialist (C). Larger lesions may require referral. Based on best available evidence, surgical excision is the first-line treatment for most nonmelanoma skin cancers, with cure rates as high as 98% with proper margins. Consider Mohs surgery for larger lesions, sclerosing lesions with morpheaform histology, or for cosmeti...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Pigmentary Disorders
سال: 2014
ISSN: 2376-0427
DOI: 10.4172/2376-0427.1000104